MannKind to Participate in the Chardan Healthcare Conference

MannKind (Nasdaq: MNKD) announced that CEO Michael Castagna will participate in a Chardan Healthcare Conference panel on October 20, 2026.

Rhea-AI Summary

MannKind (Nasdaq: MNKD) announced that CEO Michael Castagna will participate in a Chardan Healthcare Conference panel on October 20, 2026. The panel focuses on innovation in chronic respiratory diseases and runs from 2:00–2:30 p.m. ET. Management will also hold one-on-one investor meetings. A live webcast will be available on MannKind’s Investor Relations website, with a replay available for approximately 90 days following the conference.

Key Terms

idiopathic pulmonary fibrosis, antifibrotics, copd

3 terms

idiopathic pulmonary fibrosis medical

"Idiopathic Pulmonary Fibrosis"

Idiopathic pulmonary fibrosis is a chronic lung disease in which the air‑carrying tissue becomes progressively thickened and scarred for no identifiable reason, making the lungs stiff and less able to move oxygen—similar to a sponge that hardens and loses its pores. It matters to investors because it is life‑limiting with limited effective treatments, so clinical trial outcomes, regulatory approvals, pricing and reimbursement decisions can strongly affect the commercial value of therapies and the financial prospects of companies developing treatments.

antifibrotics medical

"Antifibrotics, CF, Bronchiectasis"

Antifibrotics are drugs designed to slow, stop or reverse fibrosis, the buildup of excess scar tissue that stiffens organs such as the lungs, liver or heart and reduces their function. For investors they matter because successful antifibrotic treatments can create large markets for chronic, progressive diseases; clinical trial results, regulatory approvals or setbacks quickly affect a company’s revenue prospects and valuation, similar to how an effective anti-rust treatment preserves the life and value of expensive machinery.

copd medical

"Bronchiectasis & COPD Innovation"

Chronic obstructive pulmonary disease (COPD) is a long-term lung condition that progressively narrows airways and reduces the ability to breathe, causing persistent cough, shortness of breath and fatigue. It matters to investors because a large and growing patient population creates steady demand for drugs, medical devices and care services, influences healthcare spending and regulatory decisions, and offers clear market opportunities—similar to a leaking engine that requires ongoing fixes and replacement parts.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Oct. 14, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), today announced that Chief Executive Officer Michael Castagna will participate in a panel focused on innovation across chronic respiratory diseases at the Chardan Healthcare Conference. Management will also participate in one-on-one meetings with investors during the conference.

Panel: Idiopathic Pulmonary Fibrosis & Chronic Respiratory Disease: Antifibrotics, CF, Bronchiectasis & COPD Innovation
Date: Tuesday, October 20, 2026
Time: 2:00–2:30 p.m. ET

A live webcast of the panel discussion will be available on the Events & Presentations section of MannKind’s Investor Relations website. A replay of the webcast will be available on the website for approximately 90 days following the conference.

About MannKind
MannKind Corporation (Nasdaq: MNKD) is a biopharmaceutical company dedicated to transforming chronic disease care through innovative, patient-centric solutions. Focused on cardiometabolic and orphan lung diseases, we develop and commercialize treatments that address serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease.

With deep expertise in drug-device combinations, MannKind aims to deliver therapies designed to fit seamlessly into daily life.

Learn more at mannkindcorp.com.

Contacts:
Investor Relations
Kate Miranda
ir@mnkd.com

Media Relations
Christie Iacangelo
media@mnkd.com